GE Healthcare announces a new collaboration with National Cancer Centre Singapore (NCCS), which focuses on how artificial intelligence (AI) driven research can be used to improve cancer care.
The collaboration is the first of its kind for GE Healthcare in the Asia-Pacific (APAC) region and aims to spur the potential for more tailored treatment options for specific cancer types and offer the potential to evaluate clinically significant information along the patient journey for a provider’s efficient decision making, leveraging on AI and text processing.
In 2020, there were an estimated 19 million new cancer cases in the world, with 9.7 million or 50% of them in the Asia-Pacific, according to Globocan¹. The agreement between GE Healthcare and NCCS will see the two organizations collaborate on new AI-powered solutions for data analytics and clinical workflows that support care for cancer patients in this part of the world—combining GE Healthcare’s imaging and monitoring expertise with NCCS’s deep expertise in research and development, testing and consultation.
“NCCS is one of the region’s leading centres of excellence for cancer research and treatment, and GE Healthcare is committed to supporting them in driving the transformation and advancement of cancer care pathways in Singapore and beyond. This collaboration is an important step forward in our commitment to enabling precision health through digital technology that simplifies healthcare providers’ decision-making, accelerates care delivery and has the potential to improve patient outcomes,” said Elie Chaillot, President & CEO Intercontinental at GE Healthcare.
“This new collaboration with NCCS is GE Healthcare’s first in the Asia-Pacific region that leverages AI-powered research to improve precision health practices for cancer care. Simplifying the way data is managed can help healthcare professionals improve patient outcomes with faster decision making and more precise treatment options,” said Dr. Ben Newton, General Manager Oncology at GE Healthcare.
“The National Cancer Centre Singapore continually engages the latest digital innovations to improve the delivery of cancer care for our patients. This collaboration combines the strengths of our clinical perspective and deep expertise in oncology care, analytics and translational research with GE Healthcare’s global reach, innovative technologies and services. Working together, we hope to leverage next-generation digital tools to enhance integration of cross-disciplinary information, augment clinical decision making and improve outcomes for our patients,” said Associate Professor Iain Tan, Senior Consultant and Director of Research, Division of Medical Oncology, National Cancer Centre Singapore, and Principal Investigator for this collaboration.
The collaboration is the latest in a series of alliances that GE Healthcare has established to support integrated healthcare systems at the local level through improved access to advanced AI technologies and innovations. These include collaborations with SOPHiA GENETICS in the United States and the University of Cambridge and Optellum in the United Kingdom.
 Cancer Today, Global Cancer Observatory 2020 https://gco.iarc.fr/